Literature DB >> 10395283

Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells.

E Piek1, M Afrakhte, K Sampath, E J van Zoelen, C H Heldin, P ten Dijke.   

Abstract

Activin A and osteogenic protein-1 (OP-1) exerted antagonistic effects on each other's responses on the human Tera-2 embryonal carcinoma cell line. OP-1 dose dependently inhibited activin A-induced activation of p3TP-Lux transcriptional reporter, containing part of the human plasminogen activator inhibitor-1 (PAI-1) promoter, while activin A inhibited OP-1-mediated alkaline phosphatase induction. Approximately equimolar concentrations of both growth factors resulted in 50% inhibition of the respective biological responses. Affinity cross-linking studies using 125I-activin A or 125I-OP-1 followed by receptor-immunoprecipitations revealed that both ligands bound to the activin type II receptor (ActR-II), but recruited different type I receptors. In addition, OP-1 competed with binding of 125I-activin A, and activin A competed with binding of 125I-OP-1 to ActR-II. Transient transfection studies showed that competition between activin A and OP-1 also occurred at the type I receptor (ActR-1) level; constitutively active (CA)-ActR-I inhibited CA-ActR-IB-mediated p3TP-Lux reporter induction. There was no competition between activin A and OP-1 for availability of Smad4, indicating that the concentration of this common signal transducer is not limiting for generating the observed biological responses. Overexpression of ActR-II abolished the inhibitory effect of OP-1 on activin A-induced p3TP-Lux activation and, surprisingly, led to OP-1-induced transcriptional reporter activity. Whereas the exact mechanism of competition is unclear, the role of ActR-II in the competition between activin A and OP-1 is discussed in light of the observed interference in downstream signaling by CA-ActR-I and CA-ActR-IB.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395283     DOI: 10.1002/(SICI)1097-4652(199908)180:2<141::AID-JCP1>3.0.CO;2-I

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  15 in total

1.  Loss of BMPR2 leads to high bone mass due to increased osteoblast activity.

Authors:  Jonathan W Lowery; Giuseppe Intini; Laura Gamer; Sutada Lotinun; Valerie S Salazar; Satoshi Ote; Karen Cox; Roland Baron; Vicki Rosen
Journal:  J Cell Sci       Date:  2015-02-06       Impact factor: 5.285

Review 2.  BMP signaling in vascular development and disease.

Authors:  Jonathan W Lowery; Mark P de Caestecker
Journal:  Cytokine Growth Factor Rev       Date:  2010-07-31       Impact factor: 7.638

3.  ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma.

Authors:  G H Su; R Bansal; K M Murphy; E Montgomery; C J Yeo; R H Hruban; S E Kern
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

4.  Transforming Growth Factor-β Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding.

Authors:  Senem Aykul; Erik Martinez-Hackert
Journal:  J Biol Chem       Date:  2016-03-09       Impact factor: 5.157

Review 5.  Cross-talk between nitric oxide and transforming growth factor-beta1 in malaria.

Authors:  Yoram Vodovotz; Ruben Zamora; Matthew J Lieber; Shirley Luckhart
Journal:  Curr Mol Med       Date:  2004-11       Impact factor: 2.222

6.  Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis.

Authors:  A Rebbapragada; H Benchabane; J L Wrana; A J Celeste; L Attisano
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

7.  Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume.

Authors:  Ethan Kellum; Harlan Starr; Phonepasong Arounleut; David Immel; Sadanand Fulzele; Karl Wenger; Mark W Hamrick
Journal:  Bone       Date:  2008-09-13       Impact factor: 4.398

8.  Activin signaling: effects on body composition and mitochondrial energy metabolism.

Authors:  Liunan Li; Joseph J Shen; Juan C Bournat; Lihua Huang; Abanti Chattopadhyay; Zhihong Li; Chad Shaw; Brett H Graham; Chester W Brown
Journal:  Endocrinology       Date:  2009-04-23       Impact factor: 4.736

9.  Involvement of CD9 and PDGFR in migration is evolutionarily conserved from Drosophila glia to human glioma.

Authors:  Astrid Jeibmann; Kathrin Halama; Hanna Theresa Witte; Su Na Kim; Kristin Eikmeier; Björn Koos; Christian Klämbt; Werner Paulus
Journal:  J Neurooncol       Date:  2015-07-30       Impact factor: 4.130

Review 10.  Receptor binding competition: A paradigm for regulating TGF-β family action.

Authors:  Erik Martinez-Hackert; Anders Sundan; Toril Holien
Journal:  Cytokine Growth Factor Rev       Date:  2020-10-06       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.